製品名:5-Fluoro-2-hydroxybenzoic acid

IUPAC Name:5-fluoro-2-hydroxybenzoic acid

CAS番号:345-16-4
分子式:C7H5FO3
純度:99%
カタログ番号:CM160578
分子量:156.11

包装単位 有効在庫 価格(USD) 数量
CM160578-1000g in stock ƏŭǺş

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:345-16-4
分子式:C7H5FO3
融点:-
SMILESコード:O=C(O)C1=CC(F)=CC=C1O
密度:
カタログ番号:CM160578
分子量:156.11
沸点:307.4°C at 760 mmHg
MDL番号:MFCD00002456
保管方法:Keep in a tight container and store in a cool place at ambient temperature,protect from light

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Revumenib
Syndax announced pivotal AUGMENT-101 trial of Revumenib in relapsed/refractory KMT2Ar acute leukemia met primary endpoint and stopped early for efficacy following protocol-defined interim analysis. Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including ALL and AML, and NPM1-mutant AML.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
DSP-5336
Sumitomo Pharma announces that DSP-5336 has received FDA Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a KMT2A rearrangement, also known as, mixed lineage leukemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Menin serves as a tumor suppressor in endocrine glands. Novel menin inhibitors are novel targeted agents in clinical studies targeting genetically defined subsets of acute leukemia.
DSP-5336 is an investigational menin-MLL interaction inhibitor. DSP-5336 has been granted Orphan Drug Designation in acute myeloid leukemia, and Fast Track Designation in relapsed or refractory acute myeloid leukemia with MLLr or NPM1m.